0001279569-16-004172.txt : 20160811 0001279569-16-004172.hdr.sgml : 20160811 20160811154442 ACCESSION NUMBER: 0001279569-16-004172 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160810 FILED AS OF DATE: 20160811 DATE AS OF CHANGE: 20160811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merus Labs International Inc. CENTRAL INDEX KEY: 0001031516 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30082 FILM NUMBER: 161824482 BUSINESS ADDRESS: STREET 1: 100 WELLINGTON ST. WEST STREET 2: SUITE 2110 P.O. BOX 151 CITY: TORONTO STATE: A6 ZIP: M5K 1H1 BUSINESS PHONE: 416 593-3701 MAIL ADDRESS: STREET 1: 100 WELLINGTON ST. WEST STREET 2: SUITE 2110 P.O. BOX 151 CITY: TORONTO STATE: A6 ZIP: M5K 1H1 FORMER COMPANY: FORMER CONFORMED NAME: ENVOY CAPITAL GROUP INC. DATE OF NAME CHANGE: 20090223 FORMER COMPANY: FORMER CONFORMED NAME: ENVOY COMMUNICATIONS GROUP INC DATE OF NAME CHANGE: 19970127 6-K 1 merus6k.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2016

Commission File No. 000-30082

MERUS LABS INTERNATIONAL INC.
(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151
Toronto, ON M5K 1H1
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [ ] Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]

SUBMITTED HEREWITH

Exhibits
99.1	Press Release dated August 10th, 2016 - Merus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 10, 2016

MERUS LABS INTERNATIONAL INC.

/s/ Andrew Patient
_________________________________________
Andrew Patient
Chief Financial Officer

EX-99.1 2 ex991.htm PRESS RELEASE DATED AUGUST 10TH, 2016

Exhibit 99.1

Merus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings Release

TORONTO, Aug. 10, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it will release its earnings for the third quarter of fiscal 2016 before the market opens on Monday, August 15, 2016 and hold a conference call at 8:30 am that same day to discuss the results.

The conference call can be accessed by dialing (888) 241-0551 and entering conference ID 63659805. International participants may dial (647) 427-3415. A replay of the call will be available for those not able to attend live by dialing (855) 859-2056.

In addition, Merus Labs will present at the Canaccord Genuity Growth Conference, on Thursday, August 11, 2016 at 1:30 pm at the Intercontinental Boston Hotel.

About Merus Labs

Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.

SOURCE Merus Labs Inc.

%CIK: 0001031516

For further information: Phone: (416) 593-3725, Email: info@meruslabs.com, Website: http://www.meruslabs.com/

CO: Merus Labs Inc.

CNW 12:30e 10-AUG-16